Skip to main content
S&P 5007,633.98-0.30%DOW52,472.58-0.19%NASDAQ26,282.01-0.19%BTC$78,845.00+1.95%ETH$2,533.26+0.96%GOLD$4,354.50-1.23%OIL$101.64+1.59%
Smart Investors Daily
IM

NASDAQ · IMA

ImageneBio Inc

Healthcare · Biotechnology

$5.08

Up+$0.06 (+1.18%)

Updated Sep 14, 2026, 5:20 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
72.57M
P/E ratio
-10.19
Dividend yield
0.00%
52-week range
$3.94 – $6.64
Volume
8.05K
Avg. volume
69.97K

Price performance

IMA price history

1M range · 19 trading sessions · Daily adjusted prices

IMA closed at $5.08 after 19 trading sessions, down 8.96% for the selected period.

Last close
$5.08
Period change
-8.96%
Period low
$4.85
Period high
$5.69
Daily close
View OHLC price history
IMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$5.08$5.14$4.925$5.088.05K
Sep 10, 2026$5.02$5.30$4.93$5.00522.44K
Sep 9, 2026$4.92$5.20$4.865$5.0120.94K
Sep 8, 2026$4.98$5.285$4.8901$5.0527.54K
Sep 4, 2026$4.865$4.97$4.73$4.8515.46K
Sep 3, 2026$4.89$4.94$4.81$4.88511.97K
Sep 2, 2026$5.16$5.16$4.93$4.966.24K
Sep 1, 2026$5.16$5.16$4.965$5.0212.46K
Aug 31, 2026$5.48$5.54$4.93$5.1024.6K
Aug 28, 2026$5.35$5.35$5.32$5.344.58K
Aug 27, 2026$5.43$5.50$5.33$5.3317.44K
Aug 26, 2026$5.6589$5.6589$5.365$5.439.87K
Aug 25, 2026$5.62$5.62$5.44$5.5516.83K
Aug 24, 2026$5.68$5.70$5.55$5.6213.59K
Aug 21, 2026$6.09$6.205$5.51$5.5119.94K
Aug 20, 2026$5.75$5.75$5.61$5.613.53K
Aug 19, 2026$5.9999$5.9999$5.515$5.691.67K
Aug 18, 2026$5.46$5.74$5.46$5.687.35K
Aug 17, 2026$5.89$6.015$5.58$5.5811.65K

Latest IMA news

The latest Smart Investors Daily articles mentioning IMA.

Stock researchCompany · Overview

IMA research

Overview

Company profile and research snapshot.

Company profile

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.33
Implied upside
—
Analysts
—
IMA recent ratings
DateFirmRatingTarget
Aug 21, 2026HC Wainwright & Co.Buy—
May 11, 2026WedbushUnderperform—
Oct 24, 2025Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings. H.C. Wainwright 28th Annual Global Investment Conference in New YorkFireside Chat: Monday, Sept. 14, 2026, 3:30pm ETWebcast linked here and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By